1. Home
  2. DDD vs SLN Comparison

DDD vs SLN Comparison

Compare DDD & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 3D Systems Corporation

DDD

3D Systems Corporation

HOLD

Current Price

$1.78

Market Cap

285.8M

Sector

Technology

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.14

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DDD
SLN
Founded
1986
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.8M
318.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DDD
SLN
Price
$1.78
$6.14
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$4.75
$39.67
AVG Volume (30 Days)
3.4M
309.7K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$391,651,000.00
$25,830,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.31
N/A
P/E Ratio
$17.00
N/A
Revenue Growth
N/A
40.39
52 Week Low
$1.32
$1.97
52 Week High
$5.00
$8.08

Technical Indicators

Market Signals
Indicator
DDD
SLN
Relative Strength Index (RSI) 36.88 44.28
Support Level $1.82 $6.11
Resistance Level $1.93 $6.59
Average True Range (ATR) 0.12 0.45
MACD 0.01 -0.03
Stochastic Oscillator 14.34 12.87

Price Performance

Historical Comparison
DDD
SLN

About DDD 3D Systems Corporation

3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: